EGRX—Sounds like think they have what they need, no?
Maybe. Surely, the Saudi trial could not have been any better in terms of efficacy or safety; however, the FDA may still want confirmation from a smallish US trial.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”